Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Bid For Millennium May Face Several Hurdles – Pharma Analyst

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Several factors could still prevent Japan's top drug company Takeda from acquiring U.S.-based Millennium Pharmaceuticals, a pharmaceutical analyst said in an interview with PharmAsia News

You may also be interested in...



Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees

With the national unemployment rate hitting 8.5 percent in March, the highest in 25 years, many U.S. pharmaceutical companies - once considered to have relatively strong cash reserves and traditionally immune to economic recessions - have begun slashing payrolls and announcing tens of thousands of layoffs

Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees

With the national unemployment rate hitting 8.5 percent in March, the highest in 25 years, many U.S. pharmaceutical companies - once considered to have relatively strong cash reserves and traditionally immune to economic recessions - have begun slashing payrolls and announcing tens of thousands of layoffs

Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan

Takeda and Millennium's combined oncology unit has 13 molecules in clinical development, six of which are in Phase II or III, including potential first-in-class opportunities

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel